Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Waldenstrom Macroglobulinemia 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Leukemia, Hairy Cell 1Burkitt Lymphoma 1

Interventions

pembrolizumab 311Nivolumab 159Carboplatin 158Cisplatin 140Cyclophosphamide 135Paclitaxel 129Magnetic Resonance Spectroscopy 99Specimen Handling 96Radiotherapy 93Gemcitabine 88Dexamethasone 86Biopsy 81Ipilimumab 81Docetaxel 78Doxorubicin 77Rituximab 71Etoposide 69durvalumab 62Lenalidomide 61Radiation 61atezolizumab 60Prednisone 59Pemetrexed 58Taxes 58Bevacizumab 55fludarabine 54olaparib 53Vincristine 52Cytarabine 51Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × brexucabtagene autoleucel × 1 year × Clear all
NCT02601313 2026-03-18

ZUMA-2

Gilead Sciences

Phase 2 Completed
105 enrolled 33 charts 1 FDA
Lymphoid

Lymphoma, Mantle-Cell

NCT05537766 2026-03-10

ZUMA-25

Gilead Sciences

Phase 2 Terminated
19 enrolled 28 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

NCT03642626 2026-01-23

MT2017-45: CAR-T Cell Therapy for Heme Malignancies

Masonic Cancer Center, University of Minnesota

Phase 2 Active not recruiting
150 enrolled 23 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡